Skip to main content
OpenTrials
Completed

NCT Number: NCT05768373

A Comparison Study of Hypersensitivity Treatment

The goal of this clinical trial is to evaluate the effect of 3M™ Clinpro™ Fluoride Aqueous Solution (experimental) on Dentin Hypersensitivity (DHS) in comparison to 3M™ Vanish™ (commercialized, control] in patients who have DHS.

Participants will be asked to complete the following activities:

Undergo a pre-treatment washout period for 3- to 6-weeks (± 4 days) post-enrollment. During this time, the Subject is to only use the provided oral hygiene products.

Hypersensitivity will be assessed prior to (baseline) and immediately after sample application.

Subject will be asked to come to the facility for hypersensitivity assessments at 24 hours, 7 days, and 30 days after the treatment visit.

Researchers will compare 3M™ Clinpro™ Fluoride Aqueous Solution to 3M™ Vanish™ to evaluate if the effect of Clinpro™ on DHS treatment is non-inferior to Vanish™.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

LOMA LINDA UNIVERSITY, School of Dentistry

Loma Linda, California, 92350, United States

About this study

After Informed Consent has been obtained, the subjects will be given study supplied oral hygiene products (e.g., toothbrush and toothpaste) to be used immediately after the consent visit and throughout the entire duration of the study.

Subjects will have a minimum wash-out period of 3 weeks followed by 1 treatment visit. At the treatment visit, a pain assessment will be performed (ie, a baseline pain score) in response to both an air-blast stimulus and tactile stimulus. After each stimulus, the Subject should score their pain using a Visual Analog Scale (VAS).

After recording baseline pain scores, Clinpro™ (Treatment arm) or Vanish™ (Control arm) will be applied according to the manufacturer's IFU. Pain in response to air blast and probe test will be assessed using VAS immediately after application of fluoride treatment (within 15 minutes). Pain response will be assessed again at 24 h, 7 d, 21 d and 30 d post-application of the treatment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has at least one affected hypersensitive tooth upon air blast stimuli in the cervical area, and baseline pain score of 40 mm and above as assessed by the 100 mm VAS.
  • Subject is at least 18 years old and have a minimum of 20 natural teeth.
  • Subject is willing to withhold desensitizing treatment, including prescription, in-office or over the counter (OTC) desensitizing products, throughout the study period AND withhold during the washout period.
  • Subject agrees to only use the provided toothpaste, toothbrush, and follows all oral hygiene instructions throughout the study period AND follows all oral hygiene instructions during the washout period.
  • Subject is able to understand and willing to sign the Informed Consent, and is willing to return to the study facility for scheduled study visits and recalls.

Exclusion criteria

  • Subject has medical (including psychiatric) and pharmacotherapeutic histories that may compromise the protocol - including the chronic use of anti-inflammatory, analgesic (pain), and mind-altering drugs; or analgesic (pain) medications within 48 hours prior to application of treatment.
  • Subject is pregnant (self-reported) or breast feeding.
  • Subject has allergies to product ingredients, eg, rosin, mint flavoring.
  • Subject has systemic conditions that are etiologic or predisposing to dentin hypersensitivity (eg, chronic acid regurgitation).
  • Subject has excessive dietary or environmental exposure to acids at time of screening.
  • Subject had periodontal treatment, bleaching treatments, or orthodontic treatments within previous 3 months or plans to have any other dental treatments during the study period.
  • Subject is enrolled in another clinical trial at the time of screening that would interfere with this study.
  • Subject is, in the opinion of the investigator, unsuitable for enrollment in the study for reasons other than those specified in the above exclusion criteria.

Individual teeth may not be included that meet any of the following criteria:

  • Study tooth has periodontal probing depth of ≥ 4 mm.
  • Study tooth or the surrounding supporting tissue has any other painful pathology or defects.
  • Study tooth has been restored in the preceding 3 months.
  • Study tooth is an abutment for fixed or removable prostheses or suffers traumatic malocclusion.
  • Study tooth is crowned or extensively restored and the restorations extending into the test area.
  • The tooth has dentin hypersensitivity due to cracked enamel.

Treatment and study plan

3M™ Clinpro™ Fluoride Aqueous Solution

Device

Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.

3M™ Vanish™

Device

Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.

Primary outcomes

  1. Change in Pain From Baseline Immediately After Application of Test Product.

    Time frame: Base line and immediately after application (within 15 minutes post-treatment).

    Change in sensitivity as assessed using a Visual Analog Scale (VAS, 0 - 100 mm) immediately after exposure to air stimulus relative to baseline.

    The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.

  2. Change in Pain From Baseline 24 Hours Post Application of Test Product.

    Time frame: Baseline and 24 hours post-treatment

    This is a co-primary endpoint

    Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 24 hours after exposure to air stimulus relative to baseline.

    The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.

Secondary outcomes

  1. Change in Pain From Baseline 7 Days Post Application of Test Product.

    Time frame: Baseline and 7 days post-treatment

    Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 7 days after exposure to air stimulus relative to baseline.

    The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.

  2. Change in Pain From Baseline 21 Days Post Application of Test Product.

    Time frame: Baseline and 21 days post-treatment

    Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 21 days after exposure to air stimulus relative to baseline.

    The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.

  3. Change in Pain From Baseline 30 Days Post Application of Test Product.

    Time frame: Baseline and 30 days post-treatment

    Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 30 days after exposure to air stimulus relative to baseline.

    The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.

Sponsors and collaborators

Lead sponsor

Solventum US LLC

Industry

Registry information

Official study title

Clinical Evaluation of Clinpro™ 2.1% Sodium Fluoride Aqueous Solution in the Treatment of Dentin Hypersensitivity

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Mar 14, 2023
Registry last updated
Feb 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.